Previous 10 | Next 10 |
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report...
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today ...
2023-04-03 12:32:21 ET Alimera Sciences ( NASDAQ: ALIM ) said it expanded an agreement with its distributor partner Horus Pharma for Iluvien to include Nordic countries The companies will expand their partnership beyond France, Belgium, Luxembourg and the Netherlands to boost ...
ATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it...
2023-03-31 10:57:02 ET Alimera Sciences, Inc. (ALIM) Q4 2022 Earnings Conference Call March 31, 2023 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & CEO Russell Skibsted - SVP and CFO Conference Call ...
2023-03-31 08:04:56 ET Alimera Sciences press release ( NASDAQ: ALIM ): Q4 GAAP EPS of -$0.54 misses by $0.20 . Revenue of $14.03M (+0.5% Y/Y) misses by $0.59M . As of December 31, 2022, we had approximately $5.3M in cash and cash equivalents, a decrease of $0....
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility ATLANTA, March 31, 2023 (GLOBE NEWSW...
2023-03-30 12:50:53 ET Alimera Sciences ( NASDAQ: ALIM ) is scheduled to announce Q4 earnings results on Friday, March 31th, before market open. The consensus EPS Estimate is -$0.48 (+18.6% Y/Y) and the consensus Revenue Estimate is $14.62M (+4.8% Y/Y). For further d...
2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...
2023-03-27 10:47:00 ET Gainers: Pyxis Oncology ( PYXS ) +25% . Delcath Systems DCTH +23% . Jounce Therapeutics ( JNCE ) +23% . Alimera Sciences ( ALIM ) +22% . Coeptis Therapeutics ( COEP ) +21% . Losers: Unity Biotechnology ...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...